Dyne Therapeutics (NASDAQ:DYN) Receives "Buy" Rating from Chardan Capital

Dyne Therapeutics (NASDAQ:DYN - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at Chardan Capital in a research report issued on Friday,Benzinga reports. They presently have a $50.00 price objective on the stock. Chardan Capital's target price would indicate a potential upside of 215.06% from the stock's previous close.

DYN has been the subject of a number of other reports. Robert W. Baird initiated coverage on shares of Dyne Therapeutics in a report on Friday, December 13th. They issued an "outperform" rating and a $46.00 price target for the company. Baird R W raised shares of Dyne Therapeutics to a "strong-buy" rating in a research note on Thursday, December 12th. Royal Bank of Canada began coverage on Dyne Therapeutics in a research note on Tuesday, November 26th. They issued an "outperform" rating and a $45.00 target price on the stock. Raymond James raised shares of Dyne Therapeutics to a "strong-buy" rating in a research note on Thursday, December 12th. Finally, StockNews.com downgraded shares of Dyne Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, September 16th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $49.91.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock traded down $7.18 during mid-day trading on Friday, hitting $15.87. 9,825,974 shares of the company were exchanged, compared to its average volume of 858,530. Dyne Therapeutics has a 1-year low of $14.79 and a 1-year high of $47.45. The business has a fifty day moving average of $27.29 and a 200 day moving average of $34.15.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). As a group, analysts anticipate that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Insider Activity

In related news, SVP Richard William Scalzo sold 1,455 shares of Dyne Therapeutics stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the transaction, the senior vice president now directly owns 127,078 shares in the company, valued at approximately $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Dirk Kersten sold 23,671 shares of the company's stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total transaction of $836,769.85. Following the completion of the transaction, the director now owns 99,652 shares of the company's stock, valued at approximately $3,522,698.20. This trade represents a 19.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 44,742 shares of company stock valued at $1,443,246 over the last 90 days. Insiders own 20.77% of the company's stock.

Hedge Funds Weigh In On Dyne Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Quantbot Technologies LP acquired a new position in shares of Dyne Therapeutics in the 3rd quarter valued at $34,000. Point72 DIFC Ltd bought a new position in shares of Dyne Therapeutics during the third quarter worth approximately $36,000. US Bancorp DE raised its position in Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company's stock valued at $49,000 after purchasing an additional 1,212 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Dyne Therapeutics in the 3rd quarter valued at $62,000. Finally, KBC Group NV grew its position in shares of Dyne Therapeutics by 53.4% in the 3rd quarter. KBC Group NV now owns 2,157 shares of the company's stock valued at $77,000 after buying an additional 751 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.